People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Many people with depression and anxiety in the U.S. could benefit from medication but do not receive any treatment, psychiatrist Mark Olfson told Newsweek.

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

In her new book, psychiatrist Joanna Moncrieff examines the popular belief that antidepressants "work." Among many other ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

Learn about the gut-brain connection in mental health and how targeting serotonin in the gut could revolutionise ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Postpartum depression affects many new mothers, increasing suicide risk. New research shows preventive cognitive behavioral ...

Professor Joanna Moncrieff’s new book Chemically Unbalanced further calls for greater patient consent provisions to inform ...